Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Stent wars: Shrinkage concerns resurface in Medtronic/Boston Scientific DES trial
Cordis releases 2-year data from Incraft stent trial
Cordis Corp, a Johnson & Johnson (NYSE:JNJ) subsidiary, released 2-year data from its INNOVATION trial testing the safety and performance of the Incraft abdominal aortic aneurysm stent graft system.
Abiomed hits record highs in Q3 with Impella sales up 20%
Claret Medical lands CE Mark for Sentinel device
Claret Medical’s Sentinel cerebral protection system won CE Mark approval for use providing protection against embolism during transcatheter aortic valve replacement.
The Sentinel uses a filter-based system to remove potentially dangerous embolic debris that may be dislodged during a TAVI procedure, preventing the debris from traveling to the brain. Claret plans immediately to put the device on the market, according to a press release.
Medtronic lands expanded FDA approval for Valiant Captivia
Boston Scientific donates $3.4M to Saint Luke’s cardiac research | MassDevice.com On Call
MASSDEVICE ON CALL — Massachusetts medtech giant Boston Scientific (NYSE:BSX) awarded a $3.4 million 3-year grant to support cardiac research at Saint Luke’s Mid America Heart Institute.
St. Jude touts 1st U.K. implant of ‘leadless’ Nanostim pacemaker
Corrected January 28, 2014, 11:45 a.m.
Edwards Lifesciences wins E.U. approval for next-gen Sapien 3 heart valve
Cordis S.M.A.R.T. stent still looking good at 3 years
Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. reported another year of results from its STROLL trial, which studied the durability and performance of the company’s S.M.A.R.T. vascular stent.
U.K. stent biomaterials project lands $8M grant
The ReBioStent project, led by U.K.-based Ceram, landed a $8 million (€5.8 million) grant to put towards developing new biomaterials and new arterial stents.
The ReBioStent project is seeking to develop biodegradable and biocompatible medical products, including stents. The 3-year project began this year and currently has 14 academy and industry partners working on it, according to a press release.